Longest follow up trial of Merck’s Keytruda sets new standard for five year survival in lung cancer
pharmafile | June 3, 2019 | News story | Sales and Marketing | KEYNOTE, MSD, Merck, keytruda, lung cancer
Nearly a quarter of previously untreated lung cancer patients who took Keytruda (Pembrolizumab) were alive after five years, according to the results of the longest follow-up trial for Merck’s cancer immunotherapy.
In total, 23.2% of treatment naïve patients with advanced non-small cell lung cancer (NSCLC) were alive after five years.
The data from the phase 3 KEYNOTE trial of 616 patients showed that 23.2% of previously untreated and 15.5% of previously treated patients lived for more than five years after receiving MSD’s immunotherapy.
“Lung cancer is the leading cause of cancer death, and historically, the five-year survival rate has been around 5% for patients in the U.S. with advanced non-small cell lung cancer,” said Edward B. Garon, MD, MS, associate professor of medicine, Jonsson Comprehensive Cancer Center, University of California, Los Angeles.
“As a treating physician, it is encouraging to see the results of KEYNOTE-001, in which pembrolizumab showed a five-year overall survival rate of 23.2% in treatment-naïve patients and 15.5% in previously treated patients.”
Among 60 patients who received two or more years of treatment with Keytruda, the five year overall survival rate was 78.6% in treatment naïve patients and 75.8% in previously treated patients.
“Five-year survival is a significant milestone for patients with advanced non-small cell lung cancer, and it is encouraging to see the long-term overall survival rates from our first KEYNOTE study,” said Dr. Roy Baynes, senior vice president and chief medical officer, Merck Research Laboratories.
“These five-year data provide important insights into the long-term safety and efficacy of KEYTRUDA in patients with advanced non-small cell lung cancer.”
Louis Goss
Related Content
Cizzle Biotechnology expands US rollout of lung cancer blood test
Cizzle Biotechnology has launched the commercial rollout of its CIZ1B Biomarker Blood Test for lung …
SMC accepts amivantamab and lazertinib for EGFR-positive lung cancer
The Scottish Medicines Consortium (SMC) has accepted Rybrevant (amivantamab) in combination with Lazcluze (lazertinib) for …
HUTCHMED completes enrolment in phase 3 trial for lung cancer
HUTCHMED has completed patient enrolment for the SANOVO phase 3 clinical trial, investigating the use …
